Manufactured by Eli Lilly
First of its kind: Retatrutide is not yet FDA-approved. It cannot legally be prescribed or dispensed by any pharmacy in the United States. Vials sold online with research-use-only labels are unregulated. This entry tracks the science and timeline; see /retatrutide for the full guide.
Compounded retatrutide is legally restricted as of 2025 after the FDA declared the shortage resolved. If you're currently using a compounded version, consider switching to an FDA-approved brand.
Eli Lilly's next-generation triple-agonist (GLP-1 + GIP + glucagon) weight loss injection. In late Phase 3 trials. Phase 2 results showed 24.2% body weight reduction at 48 weeks. Expected FDA decision late 2026 to early 2027.
See Retatrutide savings and coverage →FDA Status
Not FDA Approved
Route
subcutaneous injection
Typical Dose Range
1mg - 12mg weekly (Phase 3 dose range)
Dosing is determined by your prescribing provider based on your individual needs. Most GLP-1 medications follow a gradual titration schedule, starting at a low dose and increasing over several weeks to reduce side effects.
Branded (Retail)
N/A
Savings Program
N/A
Prices are estimates and may vary by pharmacy, location, and insurance coverage. Contact your provider for accurate pricing.
This is not a complete list of side effects. Talk to your healthcare provider about what to expect and when to seek medical attention.
This site is for educational purposes only and is not medical advice. Always consult a healthcare provider before starting any medication. Full disclaimer
Eli Lilly's triple-hormone retatrutide delivered up to 28.3% average weight loss in 2,339 patients, with 45% losing 30%+ body weight - surpassing all existing obesity medications.
The DoseEli Lilly's experimental triple-agonist retatrutide delivered up to 70 pounds weight loss in Phase 3 trial, matching bariatric surgery outcomes and setting new benchmark for obesity medications.
The DoseEli Lilly's triple-agonist retatrutide achieved up to 2% A1C reduction and 36.6 pounds of weight loss in its first Phase 3 diabetes trial, marking a potential new standard for type 2 diabetes treatment.
The DoseEli Lilly's triple-agonist retatrutide achieved 28.7% average weight loss (71.2 pounds) in its first successful Phase 3 trial, setting a new efficacy record for obesity medications.
